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Abstract 
The objective was to measure the impact of
exposure  to  coxibs  and  non-steroidal  anti-
inflammatory drugs (NSAID) on morbidity and
mortality in older patients with acute myocar-
dial  infarction  (AMI).  A  nested  case-control
study  was  carried  out  using  an  exhaustive
population-based  cohort  of  patients  aged  66
years  and  older  living  in  Quebec  (Canada)
who survived a hospitalization for AMI (ICD-9
410) between 1999 and 2002. The main vari-
ables were all-cause and cardiovascular (CV)
death, subsequent hospital admission for AMI,
and a composite end-point including recurrent
AMI or CV death. Conditional logistic regres-
sions were used to estimate the risk of mortal-
ity and morbidity. A total of 19,823 patients
aged 66 years and older survived hospitaliza-
tion  for  AMI  in  the  province  of  Quebec
between 1999 and 2002. After controlling for
covariables, the risk of subsequent AMI and
the  risk  of  composite  end-point  were
increased by the use of rofecoxib. The risk of
subsequent AMI was particularly high for new
rofecoxib users (HR 2.47, 95% CI 1.57-3.89).
No increased risk was observed for celecoxib
users.  No  increased  risk  of  CV  death  was
observed  for  patients  exposed  to  coxibs  or
NSAIDs.  Patients  newly  exposed  to  NSAIDs
were at an increased risk of death (HR 2.22,
95% CI 1.30-3.77) and of composite end-point
(HR 2.28, 95% CI 1.35-3.84). Users of rofecox-
ib and NSAIDs, but not celecoxib, were at an
increased risk of recurrent AMI and of com-
posite  end-point.  Surprisingly,  no  increased
risk of CV death was observed. Further studies
are needed to better understand these appar-
ently contradictory results. 
Introduction
COX-2  inhibitors  offer  a  significant  gas-
trointestinal safety advantage over non-selec-
tive  non-steroidal  anti-inflammatory  drugs
(NSAIDs).
1 However, as with any other thera-
py, potential risks associated with treatment
(in this case, increased risk of cardiovascular
events)  must  be  weighed  against  potential
benefits  (fewer  gastrointestinal  complica-
tions). In fact, the adverse effect of rofecoxib
(VIOXX) on the cardiovascular system became
apparent with the VIGOR randomized clinical
trial and seems to have now reached consen-
sus.
2-6 The effect of celecoxib on the cardiovas-
cular system is less clear. Recent meta analy-
ses  show  that  the  risk  of  acute  myocardial
infarction (AMI) associated with celecoxib is
increased in patients with a history of AMI,
5,7
but not in patients without a history of AMI.
2,3
Nevertheless, few studies show the impact of
these drugs on mortality in the general popu-
lation  and  in  the  high-risk  population  of
patients  who  survived  an  AMI.  Moreover,
among  observational  studies  evaluating  the
impact of COX-2 on mortality, the results are
very inconsistent. In Gislason et al. (2006),
5 a
very high risk of death is associated with both
celecoxib and rofecoxib in patients with prior
myocardial  infarction,  whereas  the  results
presented  in  Lee  et  al.
8 show  a  protective
effect of coxibs on overall mortality in patients
suffering from osteoarthritis. In a meta analy-
sis of randomized clinical trials, Kearney et al.
9
show a non-statistically significant increased
risk of vascular death associated with the use
of COX-2 inhibitors.  
Traditional  NSAIDs  have  also  raised  con-
cerns based on several studies reporting an
increased  risk  of  cardiovascular  events  in
users  of  these  drugs,
2,3,5 particularly  in  non-
naproxen  users.  Although  two  recent  meta
analyses
2,3 show increased cardiovascular risk
in the general population, few studies show
the impact of NSAIDs on all-cause and cardio-
vascular mortality in the general population,
and even fewer in the high-risk population of
patients  who  survived  an  acute  myocardial
infarction. Moreover, among those that specif-
ically studied mortality, we find contradictory
results.  In  Lee  et  al.,
8 the  risk  of  all-cause
death was reduced among NSAID users, even
in the high-risk population with a preexisting
coronary artery disease, and do not seem to
depend on the NSAID used (naproxen, ibupro-
fen,  diclofenac,  other  NSAID).  Similarly,
Stürmer  et  al.
10 showed  a  significant
decreased death risk associated to NSAIDs. On
the other hand, Gislason et al.
5 found a signif-
icant increased risk of death associated with
both ibuprofen and diclofenac in an AMI popu-
lation; but this risk seemed to be effective in
high daily dosage only. In low-dosage ibupro-
fen, the risk of death was even significantly
decreased. Finally, MacDonald et al.
11showed a
significant  increased  risk  of  both  all-cause
and cardiovascular death among aspirin and
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ibuprofen users as compared to aspirin alone,
but a non-significant decrease among aspirin
and diclofenac users. 
The method used to measure exposure to
drug  varied  widely.  Some  studies  considered
that  an  individual  was  exposed  to  a  specific
drug when the drug prescription overlaps the
index date,
5,12-14 when the drug has been used
within  seven  days  before  the  index  date,
15,16
when the supply of the last prescription lasted
until the index date or ended in the 30 days
before the index date,
17 or when the drug has
been prescribed within 90 days before the index
date.
18 Other studies
6,19,20 also  considered new
coxib users defined as current users who were
taking the drug for the first time in a predeter-
mined time period. Several of these studies also
categorized coxibs according to low- or high-
dosage  and  show  that  higher  dosages  imply
higher risk of acute myocardial infarction.
5,12-14
The objective of this naturalistic study was
to measure the impact in real life of exposition
to coxibs (rofecoxib, celecoxib) and NSAIDs on
morbidity and mortality in older acute myocar-
dial  infarction  (AMI)  patients.  Secondary
objectives were to explore several methods for
measuring drug exposure. 
Materials and Methods 
Design and data sources 
We  used  a  retrospective  population-based
cohort study with a nested case-control analy-
sis.  Patients’  data  were  obtained  from  the
Quebec’s provincial hospital discharge regis-
ter  (MED-ECHO)
21 and    Québec’s  provincial
demographic database which contains dates
and causes of death. These data were obtained
from the Ministère de la santé et des services
sociaux (MSSS).  The  drug  register  was
obtained from the Régie de l’assurance mal-
adie  du  Québec (RAMQ)
22 and  contains  all
drugs  claimed  by  individuals  in  the  public
drug insurance plan, which covers more than
95% of all people aged 65 years and older in
the  province.  This  database  may  represent
one of the most accurate means of determin-
ing  drugs  dispensed  to  individuals  in  real
life.
23 The coding systems differ according to
registers: the demographic register used the
International Disease Classification (ICD) -9
th
revision  before  2000  and  the  ICD-10  since
2000 for the cause of death, while the MED-
ECHO register uses the ICD-9 coding system
for diagnoses. Using a unique encrypted iden-
tifier,  patients’ files were linked to provide
individual level information on demographic
characteristics, medical and drug histories, as
well as vital status. 
Studied population 
The study population included all patients
66 years and older, living in the province of
Quebec  who  have  been  hospitalized  with  a
main diagnosis of AMI (ICD-9: 410) between
January  1999  and  December  2002.  The  first
such hospitalization during the study period
was considered as the index hospitalization.
Studies confirming the validity of the adminis-
trative hospital discharge data concerning AMI
have been  previously published.
24,25 In order to
have  only  “new”  AMI  patients,  we  excluded
patients  who  have  been  previously  hospital-
ized for an AMI in the four years before the
index  hospitalization.  We  also  excluded
patients discharged from index hospitalization
after a stay of less than four days because they
were more likely to have been misclassified as
having an AMI, and those who died within 30
days from index hospital discharge, in order to
allow some time for patients to receive medica-
tion.  A  2-year  follow-up  period  was  used  in
order to collect dates and causes of death as
well as dates and causes of subsequent hospi-
talization. 
The outcomes were all-cause death, cardio-
vascular death (ICD-9: 410-414, 426-429; ICD-
10: I20-I25, I44-I52), and rehospitalization for
AMI  (ICD-9:  410)  occurring  anytime  within
two years after cohort entry. A composite end-
point, named AMI event, was also defined and
included cardiovascular death and rehospital-
ization for AMI. Otherwise, a drug associated
with an increased mortality rate could appear
to protect against non-fatal AMI. 
Selection of cases and controls 
We used nested case-control approaches with
20 controls per case. We used 20 controls per
case to optimize statistical efficiency.
26 For each
outcome, all individuals who had the outcome
during the study follow-up were considered as
cases.  The  controls  were  matched  to  cases
according to age (within five years), gender and
date of cohort entry (within 30 days). For each
case, the controls were randomly drawn from the
case’s  matched  risk  set,  and  the  index  time
refers  to  the  time  between  the  case’s  cohort
entry and the event date. For controls, the index
time is the same as their respective case.
Table 1. Characteristics of cases and controls by outcome. 
ALL-cause death  CVD death  
Cases Controls p Cases Controls p
Number  4,146 82,784  1,963 39,177 
Age (y),
a mean (SD)   79.9(7.2) 79.1 (6.8) <0.001 80.5 (7.1) 79.6 (6.7) <0.001 
Gender,  %
Female  48.0 48.0 0.979  48.2 48.2 1.000 
Male  52.0 52.0  51.8 51.8 
Revascularization, %  10.2 24.0 <.001 9.2 22.9 <0.001 
Length of stay (days), mean (SD)  17.2 (20.3) 14.9 (16.3) <0.001 16.8 (18.2) 14.9 (16.3) <0.001 
Comorbidities, mean (SD) 3.3 (2.4) 2.1 (2.0) <0.001 3.1 (2.1) 2.0 (2.0) <0.001
Cardioprotective drug,
b % 
Aspirin  30.1 58.2 <0.001 34.3 58.2 <0.001 
Beta-blockers  27.1 54.5 <0.001  30.5 54.1 <0.001 
ACE inhibitors  29.5 54.6 <0.001  35.7 54.2 <0.001 
Statins  16.7 40.0 <0.001 20.7 38.4 <0.001 
AMI Readmission   AMI event  
Cases Controls p Cases Controls p
Number  1,759 35,167 3,240 64,695 
Age (y), mean (SD)  78.6 (7.2) 78.1 (6.8)  <0.001  79.4 (7.3) 78.8 (6.8) <0.001 
Gender, % 
Female  46.8 46.9 0.994  47.1 47.1 0.994 
Male  53.2 53.1  52.9 52.9 
Revascularization, %  13.8 25.6 <0.001  11.7 24.7 <0.001 
Length of stay (days), mean (SD)  13.3 (13.0) 14.8 (16.0) <0.001  15.3 (16.2) 15.0 (16.5) <0.001 
Comorbidities, mean (SD) 2.6 (2.1) 2.0 (2.0) <0.001 2.9 (2.2) 2.0  (2.0) <0.001
Cardioprotective drug, % 
Aspirin  55.9 58.6 0.028  45.2 58.4 <0.001 
Beta-blockers  54.5 55.2 0.584  42.4 54.7 <0.001 
ACE inhibitors  57.5 54.5 0.015  47.0 54.4 <0.001 
Statins 37.4 41.1 0.002 29.3 39.8 <0.001
aAge at cohort entry; bexposition at index timeArticle
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Drug exposure 
We considered that every patient who filled
a prescription at a pharmacy was exposed to
the drug for the length of time of the prescrip-
tion. Cases and controls were considered cur-
rently exposed if they were exposed to the drug
at index time. Past users refer to those who
were  not  currently  exposed  but  have  been
exposed in the year preceding index time, and
non-users refer to those with no prescription
of coxib or NSAIDs during that time. Another
set of analyses were performed using another
categorization: new, past and never users. New
users  refer  to  patients  who  were  currently
exposed  for  the  first  time  in  one  year,  past
users to those who were users but not for the
first time and non-users refer to the same def-
inition as before. The drug classes considered
were rofecoxib, celecoxib and NSAIDs. 
Covariables 
Other  variables  included  revascularization
at index hospitalization, index hospitalization
length  of  stay  (including  all  hospital  trans-
fers),  current  exposure  to  cardioprotective
drugs  after  hospitalization  discharge  (ASA,
ACE inhibitors, beta-blockers or statins), and a
comorbidity  index.  The  comorbidity  index,
27
which is an adaptation of the Charlson comor-
bidity index,
28 is a weighted score of comorbid
conditions; these conditions being defined by
the 16 diagnoses available in the hospital dis-
charge  database  in  the  year  preceding  and
including the index hospitalization. The pre-
dictive  performance  of  several  comorbidity
scores (including the D’Hoore index) for use
in epidemiological research with administra-
tive databases was studied by Schneeweiss et
al.
29 in 2001. They show that the four scores
based on the ICD-9 generally performed better
at predicting 1-year mortality than medication-
based Chronic Disease Score. 
Statistical analyses
For  each  outcome,  conditional  logistic
regression  model  was  used  to  estimate  the
hazard  ratios  (HR)  of  the  outcome  events
associated  with  coxibs  and  NSAIDs.  To  take
into account differences in population charac-
teristics, all models were adjusted for revascu-
larization, hospital length of stay, comorbidity
and current exposition to NSAIDs, aspirin, ACE
inhibitors and statins. All analyses were per-
formed using SAS 9.1. 
Results 
A total of 19,823 patients satisfied the inclu-
sion and exclusion criteria. During the 2-year
follow-up period, 4,146 (20.9%) patients died,
Table 2. Adjustedc hazard ratios of all-cause death according to coxib and NSAID expo-
sition: results from the conditional logistic regression analyses.
ALL-cause death  Cases  Controls  Crude HR  Adjusted HR (95% CI) 
New use 
Rofecoxib  20  429  0.91  1.18 (0.74; 1.86) 
Celecoxib  17  383  0.86  1.08 (0.66; 1.78) 
NSAID  17  185  1.79  2.22 (1.30; 3.77) * 
Past use  947  20587  0.96  1.09 (1.01; 1.18) * 
No use  3145  61200  1.00  1.00 (reference) 
Current use 
Rofecoxib  56  1366  0.80  1.13 (0.86; 1.49) 
Celecoxib  61  2138  0.56  0.76 (0.59; 0.99) * 
NSAID  36  782  0.90  1.37 (0.97; 1.94) 
Past use  838  17048  0.96  1.13 (1.04; 1.22) * 
No use  3155  61450  1.00  1.00 (reference) 
Use in last week 
Rofecoxib  70  1565  0.87  1.19 (0.93; 1.52) 
Celecoxib  88  2418  0.71  0.95 (0.76; 1.19) 
NSAID  41  897  0.89  1.28 (0.93; 1.78) 
Past use  795  16537  0.94  1.11 (1.02; 1.20) * 
No use  3152  61367  1.00  1.00 (reference) 
Use in last month 
Rofecoxib  106  2109  0.98  1.28 (1.04; 1.57) * 
Celecoxib  120  3006  0.78  1.00 (0.82; 1.21) 
NSAID  55  1236  0.87  1.23 (0.93; 1.62) 
Past use  720  15233  0.92  1.09 (1.00; 1.19) 
No use  3145  61200  1.00  1.00 (reference) 
* p<0.05; ** p< 0.001; *** p< 0.0001; cAdjusted for age, gender, time of cohort entry, revascularization and length of stay at index hospitaliza-
tion, comorbidity index, and exposure to aspirin, beta-blockers, ACE inhibitors and statins; HR,  hazard ratios.
Table 3. Adjustedd hazard ratios of cardiovascular death according to coxib and NSAID
exposition: results from the conditional logistic regression analyses. 
CV death  Cases  Controls  Crude HR  Adjusted HR (95% CI) 
New use 
Rofecoxib  8 211  0.73 0.85 (0.42; 1.76) 
Celecoxib  9  196  0.88 1.03 (0.52; 2.05) 
NSAID 7 82 1.64  2.13 (0.95; 4.76) 
Past use 430 9705 0.85  0.99 (0.89; 1.11) 
No use  1509 28983  1.00  1.00 (reference) 
Current use 
Rofecoxib  21  611 0.66  0.86 (0.55; 1.34)
Celecoxib   38 994 0.74  0.94 (0.67; 1.31) 
NSAID 17 317 0.89  1.35 (0.82; 2.21) 
Past use  375 8090 0.89  1.02 (0.90; 1.14) 
No use 1512  29115  1.00  1.00 (reference) 
Use in last week 
Rofecoxib  24  716  0.64 0.82 (0.54; 1.24) 
Celecoxib  45 1109 0.78    0.98 (0.72; 1.33) 
NSAID 17 435  0.75 1.09 (0.66; 1.78) 
Past use  366 7850 0.90 1.02 (0.91; 1.15) 
No use  1511 29067  1.00  1.00 (reference)
Use in last month 
Rofecoxib 40 968 0.79 0.99 (0.71; 1.37)
Celecoxib 61 1384 0.85 1.03 (0.79; 1.35)
NSAID 26 603 0.83 1.12 (0.75; 1.68)
Past use 327 7239 0.87 0.99 (0.87; 1.12)
No use 1509 28983 1.00 1.00 (reference)
dAdjusted for age, gender, time of cohort entry, revascularization and length of stay at index hospitalization, comorbidity index, and exposure
to aspirin, beta-blockers, ACE inhibitors and statins; HR, hazard ratios;  CV, cardiovascular.Article
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1,963 (9.9%) died from a cardiovascular dis-
ease,  1,759  (8.9%)  were  rehospitalized  for
AMI, and 3,240 (16.3%) either died from a car-
diovascular disease or were rehospitalized for
AMI. For each of these four end-points, cases
and controls were selected and are described
in Table 1. Since we matched cases and con-
trols according to gender and age, with a max-
imum difference of five years, we observe only
a slight difference in gender repartition and
average age between cases and controls. For all
study end-points, cases had less revasculariza-
tion, more comorbid conditions, and were gen-
erally  less  exposed  to  cardioprotective  treat-
ments than controls. 
The nested case-control analyses (Tables 2-
5) revealed that, after controlling for age, gen-
der, time of cohort entry, revascularization and
length of stay at index hospitalization, as well
as exposure to cardioprotective drugs, the risk
of subsequent AMI and the risk of AMI event
was increased with the use of rofecoxib, and
this was true whatever the definition of expo-
sure used (Tables 4 and 5). 
The risk of subsequent AMI was particularly
high for new rofecoxib users (HR 2.47, 95% CI
1.57-3.89, p<0.0001). Despite these findings,
the risk of cardiovascular death for patients
exposed to rofecoxib was not higher than for
patients  not  exposed  to  NSAIDs  in  the  last
year. The results also show that celecoxib was
not associated with a statistically significant
increase in the risk of any of the four end-
points. Patients newly exposed to NSAIDs were
at increased risk of death (HR 2.22, 95% CI
1.30-3.77, p=0.003) and in increased risk of
AMI  event  (HR  2.28,  95%  CI  1.35-3.84,
p=0.002), compared to non-users of NSAIDs. 
Discussion 
This study aimed to evaluate the impact of
exposition  to  coxibs  (rofecoxib,  celecoxib)
and  NSAIDs  on  mortality  and  morbidity  in
AMI patients. First, our results confirm that
exposition to rofecoxib increases the risk of
subsequent AMI. Second, as opposed to other
studies,
5,7 the exposition to celecoxib is not
associated with an increased risk of recurrent
AMI for patients with a previous history of
AMI, and this is true for all drug exposition
measures.  Furthermore,  new  users  of  rofe-
coxib  or  NSAIDs  are  at  increased  risk  of
recurrent  AMI  and  cardiovascular  event  as
compared  to  non-users  of  coxibs/NSAIDs.
Other studies
6,20 have also shown an increased
AMI risk for first time users or new users of
rofecoxib. The study of Levesque et al.
6 also
shows  a  decreased  trend  in  AMI  risk  with
increasing length of treatments. In our study,
neither exposition to rofecoxib nor exposition
to  celecoxib  were  associated  with  an
Table 4. Adjustede hazard ratios (HR) of recurrent AMI according to coxib and NSAID
exposition: results from the conditional logistic regression analyses.
Recurrent AMI  Cases  Controls  Crude HR  Adjusted HR (95% CI) 
New use 
Rofecoxib  29  325  1.73  2.47 (1.57; 3.89)*** 
Celecoxib  18  329  1.06  1.22 (0.66; 2.25) 
NSAID  16  166  1.87  1.83 (0.92; 3.64) 
Past use  734  16462  0.87  0.95 (0.85; 1.07) 
No use  2443  47413  1.00  1.00 (reference) 
Current use 
Rofecoxib  61  1015  1.16  1.68 (1.24; 2.28)** 
Celecoxib  69  1664  0.80  1.01 (0.74; 1.37) 
NSAID  37  626  1.15  1.18 (0.75; 1.84) 
Past use  616  13776  0.87  0.91 (0.81; 1.03) 
No use  2457  47614  1.00  1.00 (reference) 
Use in last week 
Rofecoxib  65  1175  1.07  1.55 (1.16; 2.09)* 
Celecoxib  83  1838  0.88  1.08 (0.81; 1.43) 
NSAID  41  749  1.06  1.18 (0.78; 1.78) 
Past use  600  13386  0.87  0.92 (0.81; 1.04) 
No use  2451  47547  1.00  1.00 (reference) 
Use in last month 
Rofecoxib  88  1587  1.08  1.46 (1.12; 1.91)* 
Celecoxib  107  2334  0.89  1.03 (0.80; 1.34) 
NSAID  57  1049  1.05  1.27 (0.90; 1.79) 
Past use  545  12312  0.86  0.91 (0.79; 1.03) 
No use  2443  47413  1.00  1.00 (reference) 
* p<0.05; ** p< 0.001; *** p< 0.0001. eAdjusted for age, gender, time of cohort entry, revascularization and length of stay at index hospital-
ization, comorbidity index, and exposure to aspirin, beta-blockers, ACE inhibitors and statins; HR, hazard ratios.
Table 5. Adjustedf hazard ratios of AMI event (recurrent AMI or CV death) according to
coxib and NSAID exposition: results from the conditional logistic regression analyses.
AMI event  Cases  Controls  Crude HR  Adjusted HR (95% CI) 
New use
Rofecoxib  20  429  0.91  1.94 (1.32; 2.86)** 
Celecoxib  17  383  0.86  1.19 (0.74; 1.93) 
NSAID  17  185  1.79  2.28 (1.35; 3.84)* 
Past use  947  20587  0.96  0.95 (0.87; 1.03) 
No use  3145  61200  1.00  1.00 (reference) 
Current use 
Rofecoxib  56  1366  0.80  1.36 (1.04; 1.77)* 
Celecoxib  61  2138  0.56  0.93 (0.73; 1.19) 
NSAID  36  782  0.90  1.39 (0.99; 1.94) 
Past use  838  17048  0.96  0.93 (0.85; 1.02) 
No use  3155  61450  1.00  1.00 (reference) 
Use in last week 
Rofecoxib  70  1565  0.87  1.23 (0.95; 1.59) 
Celecoxib  88  2418  0.71  1.00 (0.80; 1.26) 
NSAID  41  897  0.89  1.28 (0.93; 1.76) 
Past use  795  16537  0.94  0.94 (0.86; 1.03) 
No use  3152  61367  1.00  1.00 (reference) 
Use in last month 
Rofecoxib  106  2109  0.98  1.20 (0.96; 1.50) 
Celecoxib  120  3006  0.78  0.99 (0.81; 1.21) 
NSAID  55  1236  0.87  1.28 (0.98; 1.69) 
Past use  720  15233  0.92  0.93 (0.84; 1.02) 
No use  3145  61200  1.00  1.00 (reference) 
* p<0.05; ** p<0.001; *** p<0.0001; fAdjusted for age, gender, time of cohort entry, revascularization and length of stay at index hospitaliza-
tion, comorbidity index, and exposure to aspirin, beta-blockers, ACE inhibitors and statins; HR, hazard ratios.Article
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increased  risk  of  cardiovascular  mortality.
These surprising results raise some questions.
What mechanisms can explain the increased
risk of AMI associated with exposure to rofe-
coxib that is not translated to an increased risk
of cardiovascular death. A possible explanation
that has been raised by Lee et al.
8 is that the
increased risk of AMI may be counterbalanced
by a possible protective effect of improved vital-
ity or increase in physical activity because of a
more optimal control of pain. Further studies
are needed to clarify this point. 
The major strength of our study is that we
explored cardiovascular mortality as well as
cardiovascular  morbidity  when  most  of  the
studies and meta analyses explored only the
risk of AMI. We also explored several defini-
tions of coxibs exposure, which reveal that
the magnitude of the risk estimates is sensi-
tive  to  the  definition  used  to  measure  the
drug exposure but the direction remains the
same. We also performed several Cox regres-
sion  analyses  and  we  found  essentially  the
same results (data not shown). 
Our study has some limitations. First, there
may exist differences in population charac-
teristics among users and non-users of coxibs
and NSAIDs, but our analyses were all adjust-
ed for age, gender, time of cohort entry, revas-
cularization and length of stay at index hospi-
talization, comorbidity index, and exposure to
cardio-protective drug use. However, the use
of a comorbidity index that captures within a
unique variable all comorbidities can dilute
potential  confounding  factors.  Second,  the
use of administrative data did not allow us to
have  information  on  risk  factors  such  as
smoking status, body mass index, cholesterol
levels, blood pressure measurements, as well
as other known major cardiovascular risk fac-
tors, but there is no reason to believe that
these risk factors would not be evenly distrib-
uted among users and non-users. Some stud-
ies have found a positive statistically signifi-
cant association between high doses of coxib
and cardiovascular risk.
5,12-14 Unfortunately, we
were unable to take into account dosage in
our  analyses  due  to  the  limited  number  of
patients using high-dose coxib.
Finally, a major limitation could also be a
possible  information  bias  related  to  the
assumption  that  a  patient  starts  using  the
drug the day the prescription was filled at the
pharmacy,  takes  the  drug  regularly,  and  is
compliant to the posology. COX-2 inhibitors
were  drugs  dispensed  by  prescription  only.
However, the NSAID ibuprofen was the only
non-aspirin NSAID available over the counter.
Since the public drug insurance plan covers
more than 95% of all people aged 65 years and
older  in  the  province,  we  can  assume  that
only  a  small  part  of  these  patients  would
acquire medication without having data reg-
istered in the provincial database.
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